epinephrine

Manufacturer
Amneal Pharmaceuticals of New York LLC | Boehringer Ingelheim Pharma GmbH and Co. KG | Hospira, Inc. | PPD Development, L.P.
Effective date
2026-03-20
Label type
HUMAN PRESCRIPTION DRUG LABEL
Version
16
Source
full-release
Hydrated at
2026-05-31 22:10:49

Label at a glance#

Productepinephrine
Active ingredientEPINEPHRINE
Label structure20 sections

Indications and uses

Epinephrine Injection is indicated for the emergency treatment of type I allergic reactions, including anaphylaxis in adult and pediatric patients who weigh 15 kg or greater.

Dosage and administration

Recommended dosage for patients who weigh 15 kg or greater is based on weight and the dosage is provided in Table 1. Administer Epinephrine Injection intramuscularly or subcutaneously into the anterolateral aspect of the thigh. Table 1           Recommended Dosage of Epinephrine Injection Based on Patient’s Weight Patient’s Weight Dosage 30 kg or greater 0.3 mg 15 kg to less than 30 kg 0.15 mg Since the doses of e...

Storage and handling

How Supplied Epinephrine Injection is a clear and colorless solution for intramuscular or subcutaneous use. Epinephrine Injection is available as an auto-injector as described in Table 2. Table 2            Epinephrine Injection Auto-injector Package Configurations and Strengths Strength Package Configuration NDC 0.3 mg/0.3 mL Each carton contains 2 single-dose prefilled auto-injectors in individual carrier tubes ...

Label contents#

Full prescribing information#

1 INDICATIONS AND USAGE

INDICATIONS & USAGE SECTION

Epinephrine Injection is indicated for the emergency treatment of type I allergic reactions, including anaphylaxis in adult and pediatric patients who weigh 15 kg or greater.

2 DOSAGE AND ADMINISTRATION

DOSAGE & ADMINISTRATION SECTION

2.2 Administration Instructions

SPL UNCLASSIFIED SECTION

Injection:

  • 0.3 mg (0.3 mg/0.3 mL) of clear and colorless solution in single-dose pre-filled auto-injector
  • 0.15 mg (0.15 mg/0.15 mL) of clear and colorless solution in single-dose pre-filled auto-injector

3 DOSAGE FORMS AND STRENGTHS

DOSAGE FORMS & STRENGTHS SECTION

  • Injection: 0.3 mg (0.3 mg/0.3 mL) of clear and colorless solution in single-dose pre-filled auto-injector
  • Injection: 0.15 mg (0.15 mg/0.15 mL) of clear and colorless solution in single-dose pre-filled auto-injector

4 CONTRAINDICATIONS

CONTRAINDICATIONS SECTION

None.

5 WARNINGS AND PRECAUTIONS

WARNINGS AND PRECAUTIONS SECTION

5.2 Serious Infections at the Injection Site

SPL UNCLASSIFIED SECTION

Rare cases of serious skin and soft tissue infections, including necrotizing fasciitis and myonecrosis caused by Clostridia (gas gangrene), have been reported at the injection site following epinephrine injection for anaphylaxis. Clostridium spores can be present on the skin and introduced into the deep tissue with subcutaneous or intramuscular injection. While cleansing with alcohol may reduce presence of bacteria on the skin, alcohol cleansing does not kill Clostridium spores. To decrease the risk of Clostridium infection, do not inject Epinephrine Injection into the buttock [see Warnings and Precautions (5.1)]. Advise patients to seek medical care if they develop signs or symptoms of infection, such as persistent redness, warmth, swelling, or tenderness, at the epinephrine injection site.


5.3 Risks Associated with Use of Epinephrine in Certain Coexisting Conditions

SPL UNCLASSIFIED SECTION

Some patients may be at greater risk for developing adverse reactions after epinephrine administration. Despite these concerns, it should be recognized that the presence of these conditions is not a contraindication to epinephrine administration in an acute, life-threatening situation. Therefore, instruct patients with these conditions, and/or caregivers to the circumstances under which epinephrine should be used.

Administer epinephrine with caution to patients who have heart disease, including patients with cardiac arrhythmias, coronary artery or organic heart disease, or hypertension. In such patients, or in patients who are on drugs that may sensitize the heart to arrhythmias, epinephrine may precipitate or aggravate angina pectoris as well as produce ventricular arrhythmias [see Adverse Reactions (6) and Drug Interactions (7)].

Epinephrine can temporarily exacerbate the underlying condition or increase symptoms in

patients with the following: hyperthyroidism, Parkinson’s disease, diabetes, renal impairment.

Administer epinephrine with caution in patients with these conditions, including elderly patients and pregnant women.

5.4 Allergic Reactions Associated with Sulfite

SPL UNCLASSIFIED SECTION

Epinephrine is the preferred treatment for serious allergic reactions or other emergency situations even though Epinephrine Injection contains sodium bisulfite, a sulfite that may, in other products, cause allergic-type reactions including anaphylactic symptoms or life-threatening or less severe asthmatic episodes in certain susceptible persons. The alternatives to using epinephrine in a life-threatening situation may not be satisfactory. The presence of a sulfite in Epinephrine Injection should not deter administration of the drug for treatment of serious allergic or other emergency situations.

6 ADVERSE REACTIONS

ADVERSE REACTIONS SECTION

The following clinically significant adverse reactions are described elsewhere in the labeling:

The following adverse reactions associated with the use of epinephrine were identified in observational trials, case reports, studies, or postmarketing reports. Because some of these reactions were reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.

Cardiovascular: angina, arrhythmias (including fatal ventricular fibrillation), cerebral hemorrhage, hypertension, pallor, palpitations, tachyarrhythmia, tachycardia, vasoconstriction, ventricular ectopy, and stress cardiomyopathy

Gastrointestinal Disorders: nausea and vomiting

Infections: Clostridial infections (gas gangrene)

Metabolism and Nutrition Disorders: transient hyperglycemia, sweating

Neurological: disorientation, impaired memory, panic, psychomotor agitation, sleepiness,

tingling, weakness, tremor, hypoesthesia, dizziness, headache

Psychiatric: anxiety, apprehensiveness, restlessness

Respiratory: respiratory difficulties

Skin and Subcutaneous Tissue Disorders: bruising, bleeding, discoloration, erythema, necrotizing fasciitis, myonecrosis

7 DRUG INTERACTIONS

DRUG INTERACTIONS SECTION


7.1 Drugs Increasing Risk of Cardiac Arrhythmias

SPL UNCLASSIFIED SECTION

Patients who receive epinephrine while concomitantly taking cardiac glycosides, diuretics, or anti-arrhythmics should be observed carefully for the development of cardiac arrhythmias [see Warnings and Precautions (5.3) and Adverse Reactions (6)].

7.2 Drugs Potentiating Effects of Epinephrine

SPL UNCLASSIFIED SECTION

The effects of epinephrine may be potentiated by tricyclic antidepressants, monoamine oxidase inhibitors, levothyroxine sodium, and certain antihistamines, notably chlorpheniramine, tripelennamine, and diphenhydramine, and catechol-O-methyl transferase (COMT) inhibitors such as entacapone.

7.3 Drugs Antagonizing Effects of Epinephrine

SPL UNCLASSIFIED SECTION

The cardiostimulating and bronchodilating effects of epinephrine are antagonized by beta- adrenergic blocking drugs, such as propranolol.

The vasoconstricting and hypertensive effects of epinephrine are antagonized by alpha-adrenergic blocking drugs, such as phentolamine.

Ergot alkaloids may also reverse the pressor effects of epinephrine.

8 USE IN SPECIFIC POPULATIONS

USE IN SPECIFIC POPULATIONS SECTION

8.1 Pregnancy

PREGNANCY SECTION

Risk Summary

Prolonged experience with epinephrine use in pregnant women over several decades, based on published literature, have not identified a drug associated risk of major birth defects, miscarriage or adverse maternal or fetal outcomes. There are risks to the mother and fetus associated with anaphylaxis, and treatment with epinephrine should not be delayed (see Clinical Considerations). In animal reproduction studies, epinephrine administered by the subcutaneous route to pregnant rabbits, mice, and hamsters, during the period of organogenesis was teratogenic at doses 7 times and higher than the maximum recommended human intramuscular and subcutaneous dose on a mg/m2 basis (see Data).

The background risk of major birth defects and miscarriage for the indicated population is unknown. All pregnancies have a background risk of birth defect, loss, or other adverse outcomes. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2% to 4% and 15% to 20%, respectively.

Clinical Considerations

Disease-Associated Maternal and Embryo/Fetal Risk:

During pregnancy, anaphylaxis can be catastrophic and can lead to hypoxic-ischemic encephalopathy and permanent central nervous system damage or death in the mother and, more commonly, in the fetus or neonate. Treatment of anaphylaxis during pregnancy should not be delayed.

Data

Animal Data

In an embryofetal development study with rabbits dosed during the period of organogenesis, epinephrine was shown to be teratogenic (including gastroschisis and embryonic lethality) at doses approximately 40 times the maximum recommended intramuscular or subcutaneous dose (on a mg/m2 basis at a maternal subcutaneous dose of 1.2 mg/kg/day for two to three days).

In an embryofetal development study with mice dosed during the period of organogenesis, epinephrine was shown to be teratogenic (including embryonic lethality) at doses approximately 8 times the maximum recommended intramuscular or subcutaneous dose (on a mg/m2 basis at maternal subcutaneous dose of 1 mg/kg/day for 10 days). These effects were not seen in mice at approximately 4 times the maximum recommended daily intramuscular or subcutaneous dose (on a mg/m2 basis at a subcutaneous maternal dose of 0.5 mg/kg/day for 10 days).

In an embryofetal development study with hamsters dosed during the period of organogenesis from gestation days 7 to 10, epinephrine was shown to be teratogenic at doses approximately 7 times the maximum recommended intramuscular or subcutaneous dose (on a mg/m2 basis at a maternal subcutaneous dose of 0.5 mg/kg/day).

8.2 Lactation

LACTATION SECTION

Risk Summary

There is no information on the presence of epinephrine in human milk, the effects on the breastfed infants, or the effects on milk production. However, due to its poor oral bioavailability and short half-life, transfer of epinephrine into breastmilk is expected to be low. Treatment of anaphylaxis in breastfeeding patients should not be delayed.

8.4 Pediatric Use

PEDIATRIC USE SECTION

The safety and effectiveness of Epinephrine Injection for the emergency treatment of type I allergic reactions, including anaphylaxis have been established in pediatric patients who weigh 15 kg or greater. The use of Epinephrine Injection for this indication is supported by clinical experience. Clinical experience with the use of epinephrine suggests that the adverse reactions seen in pediatric patients are similar in nature and extent to those both expected and reported in adults. Since the doses of epinephrine delivered from Epinephrine Injection are fixed, use other forms of injectable epinephrine if doses lower than 0.15 mg are deemed necessary.

The safety and effectiveness of Epinephrine Injection have not been established in pediatric patients who weigh less than 15 kg.

8.5 Geriatric Use

GERIATRIC USE SECTION

Clinical studies of Epinephrine Injection for emergency treatment of type I allergic reactions, including anaphylaxis, were not conducted in geriatric patients aged 65 and over to determine whether they respond differently from younger adult patients. However, other reported clinical experience with use of epinephrine for the treatment of anaphylaxis has identified that geriatric patients may be particularly sensitive to the effects of epinephrine. Therefore, these patients may be at greater risk for developing adverse reactions after epinephrine administration.

10 OVERDOSAGE

OVERDOSAGE SECTION

Overdosage of epinephrine has been reported to produce extremely elevated arterial pressure, which may result in cerebrovascular hemorrhage, particularly in elderly patients. Overdosage may also result in pulmonary edema because of peripheral vascular constriction together with cardiac stimulation.

Epinephrine overdosage can also cause transient bradycardia followed by tachycardia which may be accompanied by fatal cardiac arrhythmias; premature ventricular contractions followed by multifocal ventricular tachycardia; atrial tachycardia and occasionally by atrioventricular block; extreme pallor and coldness of the skin; metabolic acidosis; kidney failure.

Epinephrine is rapidly inactivated in the body and treatment following overdosage with epinephrine is primarily supportive. Treatment of epinephrine associated pulmonary edema consists of a rapidly acting alpha-adrenergic blocking drug (such as phentolamine mesylate) and respiratory support. Treatment of epinephrine associated arrhythmias consists of administration of a beta-adrenergic blocking drug (such as propranolol). If necessary, pressor effects may be counteracted by rapidly acting vasodilators or α-adrenergic blocking drugs. If prolonged hypotension follows such measures, it may be necessary to administer another pressor drug.

Consider contacting the Poison Help line (1-800-222-1222) or a medical toxicologist for additional overdosage management recommendations.

11 DESCRIPTION

DESCRIPTION SECTION

Epinephrine Injection, USP 0.3 mg and 0.15 mg, are single-dose auto-injectors and combination products containing drug and device components.

Each Epinephrine Injection, USP 0.3 mg, delivers a single dose of 0.3 mg epinephrine from Epinephrine Injection, USP (0.3 mL) in a sterile solution.

Each Epinephrine Injection, USP 0.15 mg, delivers a single dose of 0.15 mg epinephrine from Epinephrine Injection, USP (0.15 mL) in a sterile solution.

Epinephrine Injection, USP 0.3 mg and Epinephrine Injection, USP 0.15 mg each contain 1.1 mL of epinephrine solution. 0.3 mL and 0.15 mL epinephrine solution are dispensed for Epinephrine Injection, USP 0.3 mg and Epinephrine Injection, USP 0.15 mg, respectively, when activated. The solution remaining after activation is not available for future use and should be discarded.

Each 0.3 mL in Epinephrine Injection, USP 0.3 mg, contains 0.3 mg epinephrine, 2.6 mg sodium chloride, not more than 1.5 mg chlorobutanol, 0.45 mg sodium bisulfite, hydrochloric acid and sodium hydroxide to adjust pH, and water for injection. The pH range is 2.2-5.0.

Each 0.15 mL in Epinephrine Injection, USP 0.15 mg, contains 0.15 mg epinephrine, 1.3 mg sodium chloride, not more than 0.75 mg chlorobutanol, 0.225 mg sodium bisulfite, hydrochloric acid and sodium hydroxide to adjust pH, and water for injection. The pH range is 2.2-5.0.

Epinephrine is a sympathomimetic catecholamine. Chemically, epinephrine is (-)-3,4-Dihydroxy-α-[(methylamino)methyl]benzyl alcohol with the following structure:

Chemical Structure
Chemical Structure

Epinephrine solution deteriorates rapidly on exposure to air or light, turning pink from oxidation to adrenochrome and brown from the formation of melanin. Replace Epinephrine Injection, USP if the epinephrine solution appears discolored (pinkish or brown color), cloudy, or contains particles.

12 CLINICAL PHARMACOLOGY

CLINICAL PHARMACOLOGY SECTION

12.1 Mechanism of Action

MECHANISM OF ACTION SECTION

Epinephrine acts on both alpha- and beta-adrenergic receptors.

Through its action on alpha-adrenergic receptors, epinephrine lessens the vasodilation and increased vascular permeability that occurs during anaphylaxis, which can lead to loss of intravascular fluid volume and hypotension.

Through its action on beta-adrenergic receptors, epinephrine causes bronchial smooth muscle relaxation and helps alleviate bronchospasm, wheezing, and dyspnea that may occur during anaphylaxis.

Epinephrine also alleviates pruritus, urticaria, and angioedema, and may relieve gastrointestinal and genitourinary symptoms associated with anaphylaxis because of its relaxer effects on the smooth muscle of the stomach, intestine, uterus and urinary bladder.

12.2 Pharmacodynamics

PHARMACODYNAMICS SECTION

When given subcutaneously or intramuscularly, epinephrine has a rapid onset and short duration of action.

13 NONCLINICAL TOXICOLOGY

NONCLINICAL TOXICOLOGY SECTION

13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility

CARCINOGENESIS & MUTAGENESIS & IMPAIRMENT OF FERTILITY SECTION

Long-term studies to evaluate the carcinogenic potential of epinephrine have not been conducted.

Epinephrine and other catecholamines have been shown to have mutagenic potential in vitro. Epinephrine was positive in the Salmonella bacterial reverse mutation assay, positive in the mouse lymphoma assay, and negative in the in vivo micronucleus assay. Epinephrine is an oxidative mutagen based on the E. coli WP2 Mutoxitest bacterial reverse mutation assay. This should not prevent the use of epinephrine where indicated [see  Indications and Usage (1)].

The potential for epinephrine to impair reproductive performance has not been evaluated, but epinephrine has been shown to decrease implantation in female rabbits dosed subcutaneously with 1.2 mg/kg/day (40-fold the highest human intramuscular or subcutaneous daily dose) during gestation days 3 to 9.

16 HOW SUPPLIED/STORAGE AND HANDLING

HOW SUPPLIED SECTION

How Supplied

Epinephrine Injection is a clear and colorless solution for intramuscular or subcutaneous use. Epinephrine Injection is available as an auto-injector as described in Table 2.

Table 2            Epinephrine Injection Auto-injector Package Configurations and Strengths

Strength

Package Configuration

NDC

0.3 mg/0.3 mL

Each carton contains 2 single-dose prefilled auto-injectors in individual carrier tubes

NDC 0115-1694-49

Auto-injector in carrier tube

NDC 0115-1694-30

0.15 mg/0.15 mL

Each carton contains 2 single-dose prefilled auto-injectors in individual carrier tubes

NDC 0115-1695-49

Auto-injector in carrier tube

NDC 0115-1695-30

Storage and Handling

  • Protect from light. Epinephrine Injection is light sensitive and should be stored in the individual carrier tube provided.
  • Store at 20°C to 25°C (68°F to 77°F); excursions permitted to 15°C to 30°C (59°F to 86°F) [See USP Controlled Room Temperature].
  • Do not refrigerate or freeze.
  • Before using, check to make sure the solution in the auto-injector is clear and colorless.
  • Replace the auto-injector if the solution is discolored (pinkish or brown color), cloudy, or contains particles.
  • Properly dispose of all used, unwanted, or expired Epinephrine Injection, USP.

17 PATIENT COUNSELING INFORMATION

INFORMATION FOR PATIENTS SECTION

Advise the patient to read the FDA-approved patient labeling (Patient Information and Instructions for Use).

Administration

  • Each Epinephrine Injection contains a single dose of epinephrine for single use.
  • Instruct patients and/or caregivers to inspect the epinephrine solution visually through the viewing window periodically. Epinephrine Injection should be replaced if the epinephrine solution appears discolored, cloudy, or contains particles.
  • Instruct patients and/or caregivers on proper intramuscular or subcutaneous injection technique using the Epinephrine Injection Trainer. A Trainer device is not provided with epinephrine injection. Patients and/or caregivers may obtain a Trainer device at www.epinephrineautoinject.com. Instructions for use of the Trainer device are provided on the Trainer label. Instruct patients and/or caregivers to use the Trainer to familiarize themselves with the use of epinephrine injection in an allergic emergency. The Trainer device may be used multiple times.

    For additional video instructions on the use of epinephrine injection,go to www.epinephrineautoinject.com.

  • Instruct caregivers to hold the leg of young children or infants firmly in place and limit movement prior to and during injection. [see Warnings and Precautions (5.2)].
  • Instruct patients and/or caregivers in the appropriate use of Epinephrine Injection.Epinephrine Injection should be injected into the middle of the outer thigh (through clothing if necessary).
  • Instruct patients and/or caregivers when a second dose of Epinephrine Injection is needed. Administer a new Epinephrine Injection into the middle of the outer thigh starting 5 minutes after the first dose.
  • Advise patients and/or caregivers when to seek emergency medical care for close monitoring of the type I allergic emergency and in the event that further treatment is required.

Injection-Related Complications

Advise patients to seek immediate medical care in the case of accidental injection into the digits, hands or feet because such an accidental injection to these areas may cause loss of blood flow to the affected area [see Warnings and Precautions (5.1)].

Serious Infections at the Injection Site

Advise patients that rare cases of serious skin and soft tissue infections, including necrotizing fasciitis and myonecrosis caused by Clostridia (gas gangrene), have been reported at the injection site following injection of epinephrine for anaphylaxis. Instruct patients to seek medical care if they develop signs or symptoms of infection, such as persistent redness, warmth, swelling, or tenderness, at the Epinephrine Injection site [see Warnings and Precautions (5.2)].

Risks Associated with Certain Coexisting Conditions

Advise patients with coexisting conditions (cardiac arrhythmia and ischemia, coronary artery disease, hypertension, pulmonary edema, hyperthyroidism, renal impairment, Parkinson's disease, diabetes), for increased risks that may be associated with use of epinephrine [see Warnings and Precautions (5.3)].

Storage and Handling

Epinephrine Injection is light sensitive and should be stored in the individual carrier tube provided to protect it from light. The individual carrier tube is not waterproof. Instruct patients that Epinephrine Injection must be properly disposed of once the blue end caps have been removed or after use [see How Supplied/Storage and Handling (16)].

Manufactured for and Distributed by:

Amneal Pharmaceuticals LLC

Bridgewater, NJ 08807

© 2025 Amneal Pharmaceuticals LLC. All rights reserved.

For inquiries call 1-877-835-5472

1871-05

Rev. 03-2026-05

PATIENT INFORMATION

SPL PATIENT PACKAGE INSERT SECTION

PATIENT INFORMATION

EPINEPHRINE injection (ep″ i nef′ rin),

for intramuscular or subcutaneous use

Epinephrine Injection USP, 0.3 mg

Each Epinephrine Injection USP, 0.3 mg delivers a single dose of 0.3 mg epinephrine USP, in 0.3 mL (0.3 mg/0.3 mL)

Epinephrine Injection USP, 0.15 mg

Each Epinephrine Injection USP, 0.15 mg delivers a single dose of 0.15 mg epinephrine USP, in 0.15 mL (0.15 mg/0.15 mL)

For allergic emergencies (anaphylaxis)

Read this Patient Information leaflet carefully before you use Epinephrine Injection and each time you get a refill. There may be new information. You, your parent, caregiver, or others who may be able to administer Epinephrine Injection should know how to use it before you have an allergic emergency. This information does not take the place of talking with your healthcare provider about your medical condition or your treatment.

What is the most important information I should know aboutEpinephrine Injection?

1. Epinephrine Injection is a medicine used to treat allergic emergencies (anaphylaxis). Anaphylaxis can be life-threatening and can happen within minutes. If untreated, anaphylaxis can lead to death.

Allergic emergencies may be caused by stinging and biting insects, allergy injections, foods, medicines, exercise, or other unknown causes.

Symptoms of anaphylaxis may include:

  • trouble breathing
  • wheezing
  • hoarseness (changes in the way your voicesounds)
  • hives (raised reddened rash that may itch)
  • severe itching
  • swelling of your face, lips, mouth, or tongue
  • skin rash, redness, or swelling
  • fast heartbeat
  • weak pulse
  • feeling very anxious
  • confusion
  • stomach pain
  • losing control of urine or bowel movements (incontinence)
  • diarrhea or stomach cramps
  • dizziness, fainting, or “passing out” (unconsciousness)

2. It is recommended that people are prescribed and have immediate access to 2 Epinephrine Injection devices at all times. Sometimes a single dose of epinephrine may not be enough to treat a serious allergic reaction before seeking emergency medical help. You should also have immediate access to 2 Epinephrine Injection devices in case the first device is activated before the dose can be given. A device that has been activated accidentally cannot be used to treat an allergic emergency (anaphylaxis).

Note: Epinephrine Injection has been activated if you see the needle sticking out of the red needle end and the viewing window is blocked.

You may not know when an allergic emergency (anaphylaxis) will happen.

Talk to your healthcare provider if you need additional Epinephrine Injection devices to keep at work, school, or other locations. If you use 1 Epinephrine Injection device to treat an emergency allergic reaction, be sure to replace it so you always have immediate access to 2 devices. Tell your family members, caregivers, and others where you keep your Epinephrine Injection. Make sure they know how to use it before you need it. You may be unable to speak in an allergic emergency.

3. When you have an allergic emergency (anaphylaxis) use Epinephrine Injection right away.

Get emergency medical help for further treatment of the allergic emergency (anaphylaxis), if needed, after using Epinephrine Injection. Before you receive Epinephrine Injection, your healthcare provider should talk to you about when to get emergency help.

If symptoms do not improve or if they worsen after the first dose, or you accidentally inject Epinephrine Injection intothe fingers, toes, hands or feet, a second dose of Epinephrine Injection may be administered with a second auto-injector starting 5 minutes after the first dose. If more than 2 doses are needed for an allergic emergency, they must be given by a healthcare provider.

What isEpinephrine Injection?

  • Epinephrine Injection is a medicine used to treat life-threatening allergic emergencies (anaphylaxis). It is delivered using a disposable, prefilled automatic injection device (auto-injector). Each auto-injector contains a single dose of epinephrine.
  • Epinephrine Injection is for immediate administration by you or your caregiver. Get emergency medical help, if needed, after using Epinephrine Injection. Your healthcare provider should talk to you about when to get emergency help.
  • Epinephrine Injection is for people who have been prescribed this medicine by their healthcare provider.
  • The Epinephrine Injection 0.3 mg auto-injector is for people who weigh 66 pounds or greater.
  • The Epinephrine Injection 0.15 mg auto-injector is for people who weigh 33 pounds to less than 66 pounds.
  • It is not known if Epinephrine Injection is safe and effective in children who weigh less than 33 pounds.

What should I tell my healthcare provider before using Epinephrine Injection?

Before you use Epinephrine Injection, tell your healthcare provider about all your medical conditions. Your healthcare provider may give you more instructions about when and how to use your Epinephrine Injection if you have the following:

  • heart problems or high blood pressure
  • diabetes
  • thyroid problems
  • asthma
  • a history of depression
  • Parkinson’s disease
  • kidney (renal) problems

    You may also receive more instructions if you:

  • are pregnant or plan to become pregnant. It is not known if epinephrine will harm your unborn baby.
  • are breastfeeding or plan to breastfeed. It is not known if epinephrine passes into your breast milk.

Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins and herbal supplements. Also tell your healthcare provider about all known allergies. Some medicines may increase or decrease the effects of epinephrine, and epinephrine may affect how other medicines work.

Know the medicines you take. Keep a list of all your medicines, including over-the-counter medicines, vitamins and herbal supplements to show your healthcare provider and pharmacist when you get a new medicine.

Use your Epinephrine Injection for treatment of anaphylaxis as prescribed by your healthcare provider, regardless of your medical conditions or the medicine you take.

How should I useEpinephrine Injection?

  • Use your single-dose Epinephrine Injection exactly as your healthcare provider tells you to use it.
  • When you have an allergic emergency (anaphylaxis), use Epinephrine Injection right away. Get emergency medical help, if needed, after using Epinephrine Injection.
  • You may need to use a second Epinephrine Injection if symptoms continue or come back after the first dose. A second dose may be administered starting 5 minutes after the first dose while you wait for emergency medical help, or if the first Epinephrine Injection is activated before the dose can be given. If you need more than 2 doses of epinephrine for a single anaphylaxis episode, additional doses must be given by a healthcare provider.
  • Epinephrine Injection should only be injected into the middle of the outer thigh (upper leg). It can be injected through clothing if needed.
  • Do not inject into a vein, buttocks, fingers, toes, hands or feet.If Epinephrine Injection is injected into the fingers, toes, hands or feet, administer a second dose of Epinephrine Injection into the middle of the outer thigh (upper leg). If symptoms worsen or persist, go immediately to the nearest emergency room for further treatment of anaphylaxis.
  • Read and make sure you understand the Instructions for Use for information about the correct way to use Epinephrine Injection.
  • Your healthcare provider will show you how to safely use Epinephrine Injection.
  • It is very important that you hold Epinephrine Injection firmly against the middle of the outer thigh (upper leg) for a full 10 seconds. If you do not hold it in place long enough, Epinephrine Injection may not deliver the full dose of medicine.
  • Caution: Never put your thumb, fingers, or hand over the red needle end. Never press or push the red needle end with your thumb, fingers, or hand.The needle comes out of the red needle end. Accidental injection into the fingers, hands, or feet may cause a loss of blood flow to those areas. If this happens, give a second dose of Epinephrine Injection into the middle of the outer thigh (upper leg) and go immediately to the nearest emergency room. Tell the healthcare provider where on your body the injection occurred.
  • Warning: After the device is activated, the needle does not retract back into the device. After use, carefully place the used auto-injector into the carrier tube, if possible, and throw away (dispose of) it properly as directed.
  • See the Instructions for Use for detailed information on how to safely handle and throw away (dispose of) the used auto-injector.
  • Epinephrine Injection is packaged in a carton containing 2 Epinephrine Injections auto-injectors, each in an individual carrier tube.
  • Do not drop the carrier tube or Epinephrine Injection. If the carrier tube or Epinephrine Injection is dropped, check for damage or leakage. Throw away (dispose of) and replace Epinephrine Injection if damage or leakage is noticed or suspected.
  • You may request a separate Trainer at www.epinephrineautoinject.com. The epinephrine injection Trainer has a beige color. The beige epinephrine injection Trainer contains no medicine and no needle. Practice using the Trainer before an allergic emergency occurs so you know how to use Epinephrine Injection correctly. Always carry your real Epinephrine Injection, USP auto-injector with you in case of an allergic emergency.

What are the possible side effects ofEpinephrine Injection?

Epinephrine Injection may cause serious side effects.

Injection-related complications

  • Epinephrine Injection should only be injected into the middle of your outer thigh (upper leg). Do not inject Epinephrine Injection into a vein, buttocks, fingers, toes, hands, or feet. If you accidentally inject Epinephrine Injection into any other part of your body, administer a second dose of Epinephrine Injection into the middle of the outer thigh (upper leg) and go to the nearest emergency room right away. Tell the healthcare provider where on your body the injection occurred.

Serious infections at the injection site

  • Rarely, people who have used Epinephrine Injection may develop serious skin and soft tissue infections at the injection site within a few days after injection. Call your healthcare provider right away if you notice any of the following at the injection site:

    o redness that does not go away

    o swelling

    o tenderness

    o warmth at the injection site

    Other side effects

  • If you have certain medical conditions, or take certain medicines, your condition may get worse or you may have more or longer lasting side effects when you use Epinephrine Injection. Talk to your healthcare provider about all of your medical conditions.

Common side effects of Epinephrine Injection include:

  • fast, irregular or “pounding” heartbeat
  • sweating
  • headache
  • weakness
  • shakiness
  • paleness
  • feelings of excitement, nervousness or anxiety
  • dizziness
  • ·nausea or vomiting
  • breathing problems

These side effects may go away with rest. Tell your healthcare provider if you have any side effect that bothers you or that does not go away.

These are not all the possible side effects of Epinephrine Injection. For more information, ask your healthcare provider or pharmacist.

Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.

You may also report side effects to Amneal Pharmaceuticals LLC at 1-877-835-5472.

How should I storeEpinephrine Injection?

  • Store Epinephrine Injection at room temperature between 68°F to 77°F (20°C to 25°C).
  • Keep Epinephrine Injection in the individual carrier tube provided to protect it from light and damage. The carrier tube is not waterproof.
  • Do not expose Epinephrine Injection to extreme heat or cold. For example, do not store in your vehicle’s glove box and do not store it in the refrigerator or freezer.
  • Periodically examine the solution through the viewing window of your Epinephrine Injection. The solution should be clear and colorless. Replace Epinephrine Injectionif the solution appears discolored (pinkish or brown), cloudy, or contains particles.
  • The blue needle shield cap and blue end cap helps to prevent accidental injection. Do not remove the blue needle shield cap or blue end caps until you are ready to use Epinephrine Injection. After the auto-injector is used, throw away the blue end caps immediately, as they may pose a choking hazard for young children.
  • Keep Epinephrine Injection and all medicines out of the reach of children.

    Disposing of an Expired, Unused or Used Epinephrine Injection

  • Your Epinephrine Injection has an expiration date. Replace it before the expiration date.
  • Throw away (dispose of) expired, unwanted, or unused Epinephrine Injections in an FDA-cleared sharps disposal container. Do not throw away Epinephrine Injection in your household trash. If you do not have an FDA-cleared sharps disposal container, you may use a household container that is:
  • Made of heavy-duty plastic,
  • Can be closed with a tight-fitting, puncture-resistant lid, without sharps being able to come out,
  • Upright and stable during use,
  • Leak-resistant, and
  • Properly labeled to warn of hazardous waste inside the container.

When your sharps disposal container is almost full, follow your community guidelines for proper disposal. There may be state or local laws about how you should dispose of used needles and syringes. For more information about safe sharps disposal, visit the FDA website at fda.sharepoint.com/sites/CDER-NDR-OND-II-PACC/Marketing%20Applications/NDA%20020800%20S-054/2026_01_30%20Label%20from%20applicant/www.fda.gov/safesharpsdisposal.

General information about the safe and effective use of Epinephrine Injection:

Medicines are sometimes prescribed for purposes other than those listed in a Patient Information leaflet. Do not use Epinephrine Injection for a condition for which it was not prescribed. Do not give Epinephrine Injection to other people.

This Patient Information leaflet summarizes the most important information about Epinephrine Injection. If you would like more information, talk to your healthcare provider. You can ask your pharmacist or healthcare provider for information about Epinephrine Injection that is written for health professionals.

For more information and video instructions on the use of Epinephrine Injection, go to www.epinephrineautoinject.com or call 1-877-835-5472.

What are the ingredients inEpinephrine Injection?

Active Ingredient: epinephrine

Inactive Ingredients: sodium chloride, chlorobutanol, sodium bisulfite, hydrochloric acid, sodium hydroxide, and water.

Important Information

  • TheEpinephrine Injection, 0.3 mg auto-injector has a yellow-colored label.
  • The Epinephrine Injection, 0.15 mg auto-injector has an orange-colored label.
  • The Epinephrine Injection Trainer has a beige color, and contains no medicine and no needle.
  • Your Epinephrine Injection is designed to work through clothing.
  • The blue needle shield cap and the blue end cap on Epinephrine Injection help to prevent accidental injection of the device. Do not remove the blue needle shield cap and blue end caps until you are ready to use it.
  • Choking hazard: The blue needle shield cap and blueend caps are small parts that may become a choking hazard for children. Throw away the blue end caps immediately after use.
  • Only inject into the middle of the outer thigh (upper leg). Never inject into any other part of the body.
  • Never put your thumb, fingers, or your hand over the red needle end. The needle comes out of the red needle end.
  • If an accidental injection happens, get medical help right away.
  • Do not place patient information or any other foreign objects in carrier with the auto-injector, as this may prevent you from removing Epinephrine Injection for use.

 

Incorrect Use and Correct Use of Epinephrine Injection

Incorrect Use

Correct Use and Important Reminders

Storing Epinephrine Injection outside the carrier tube.

Always keep Epinephrine Injection stored in the individual carrier tube provided to protect it from light and damage. The carrier tube is not waterproof.

Storing of the Epinephrine Injection outside of the recommended storage conditions.

Always keep your Epinephrine Injection stored at room temperature (68°F to 77°F / 20°C to 25°C).

Failing to remove the Epinephrine Injection from the carrier tube before use.

Remove Epinephrine Injection from the carrier tube before use.

Failing to remove both the blue caps in proper sequence before use.

Before use, remove the blue needle shield cap first to expose the red needle end. Then remove the blue end cap.

Failing to remove both blue caps before use.

Epinephrine Injection will not activate or deliver the dose if both blue caps are not removed.

Failing to remove the blue caps in the proper order.

Removing the blue caps in the incorrect order may cause premature activation of Epinephrine Injection.

Failing to remove the blue needle shield cap properly, resulting in the needle sheath remaining in place.

Pull off the blue needle shield cap by grasping the ribbed area and pulling straight off until the red needle end is visible. Do not squeeze the non-ribbed area.

Activating Epinephrine Injection upside down, resulting in injection into the hand.

The needle exits from the red needle end, which must be placed against the middle of the outer thigh (upper leg) at a 90˚ angle (perpendicular) before and during activation.

Failing to apply enough force to activate Epinephrine Injection.

Press down hard and hold Epinephrine Injection firmly against the outer thigh at a 90˚ angle for 10 seconds.

Do not swing or jab the device.

Expecting an audible click to confirm activation.

You may or may not hear a sound when the injection starts.

Assuming the dose was not delivered because liquid remains in the device.

It is normal for most of the medicine to remain in the auto-injector after the dose is delivered. The dose has been delivered if the needle is visible after use.

Administering at an injection site other than the outer thigh.

Inject Epinephrine Injection only into the middle of the outer thigh (upper leg).

Removing the device at an angle, causing needle bending.

Place the red needle end against the thigh at a 90° angle (perpendicular), press down firmly, and remove the device straight out at a 90° angle after injection.

Failing to hold Epinephrine Injection in place long enough.

Hold Epinephrine Injection firmly in place for a full 10 seconds to ensure dose delivery.

Failing to locate the expiration date.

Remove Epinephrine Injection from the carrier tube. The expiration date is located on the auto-injector label.

 

For more information and video instructions on the use of Epinephrine Injection, go to www.epinephrineautoinject.com or call 1-877-835-5472.

This Patient Information has been approved by the U.S. Food and Drug Administration                                                                                   Rev. 03/2026


Instructions for Use

INSTRUCTIONS FOR USE SECTION

EPINEPHRINE injection (ep″ i nef′ rin),

for intramuscular or subcutaneous use

Epinephrine Injection USP, 0.3 mg

Each Epinephrine Injection USP, 0.3 mg delivers a single dose of 0.3 mg epinephrine USP in 0.3 mL (0.3 mg/0.3 mL)

Epinephrine Injection USP, 0.15 mg

Each Epinephrine Injection USP, 0.15 mg delivers a single dose of 0.15 mg epinephrine USP in 0.15 mL (0.15 mg/0.15 mL)

For allergic emergencies (anaphylaxis)

This Instructions for Use contains information on how to properly administer Epinephrine Injection.

Your Epinephrine Injection

fig A
fig A

Figure A. Epinephrine Injection, USP 0.3 mg (yellow label) and

Epinephrine Injection, USP 0.15 mg (orange label), showing the auto-injector and carrier tube components

 

Important Information You Need to Know Before Administering Epinephrine Injection

  • Epinephrine Injection is a single-dose auto-injector used for allergic emergencies (anaphylaxis) and should be used right away.
  • Before you need to use your Epinephrine Injection, make sure your healthcare provider shows you the right way to use it. Anyone who may be able to administer Epinephrine Injection should also understand how to use it.
  • Check the expiration date on your Epinephrine Injection, as shown inFigure A. Replace it before the expiration date.
  • Read this Instructions for Use carefully in a non-emergency situation and make sure you understand them before using your Epinephrine Injection. If you have any questions, ask your healthcare provider.
  • It is very important to hold Epinephrine Injection firmly in place for a full 10 seconds. If you do not hold it in place long enough, Epinephrine Injection may not have time to deliver the full dose of medicine.
  • Always carry 2 Epinephrine Injection devices. One dose may not be enough to treat an allergic emergency. You may need to use a second Epinephrine Injection if symptoms continue or come back after the first dose. A second dose may be administered starting 5 minutes after the first dose while you wait for emergency medical help, or if the first Epinephrine Injection is activated before the dose can be given.
  • Inject Epinephrine Injection into the muscle (intramuscular) or under the skin (subcutaneous) in the middle of the outer thigh (upper leg) (see Figure B). Do not inject Epinephrine Injection into any other part of the body.
  • If you accidentally inject Epinephrine Injection into the fingers, toes, hands or feet, administer a second dose of Epinephrine Injection into the middle of the outer thigh (upper leg).
  • Epinephrine Injection can be administered through clothing if needed.
b
b

Figure B. Inject Epinephrine Injection into the middle of the outer thigh (upper leg)

 

Each Epinephrine Injection is for single use only.

The dose has been delivered if you see the needle sticking out of the red needle end after use. It is normal for most of the medicine to remain in the auto-injector after the dose is injected.

  • Do not take the Epinephrine Injection apart.
  • Do not remove the blue needle shield cap and blue end cap until you are ready to use Epinephrine Injection.
  • Always point the red needle end downward (see Figure C). Never put your thumb, fingers, or hand over the red needle end. The needle comes out of the red needle end.
  • Accidental injection into the fingers, hands, or feet may cause loss of blood flow to these areas. If an accidental injection happens, get emergency medical help right away.
c
c

Figure C. Correct way to hold the Epinephrine Injection with red needle end pointing down

 

Preparing to Inject Epinephrine Injection

Read the following information while preparing to inject Epinephrine Injection:

  • Epinephrine Injectioncan be administered through clothing. Remove any objects or clothing that may block access to the injection site.
  • Check Epinephrine Injectionbefore use. If the auto-injector appears damaged or broken, do not use it. Throw away (dispose of it) and use a new Epinephrine Injection.
  • A separate Epinephrine Injection Trainer is available. The Trainer is beige in color and contains no medicine and no needle. Practice using the Trainer, but always carry your real Epinephrine Injection in case of an allergic emergency.
  • You may request a separate Trainer at www.epinephrineautoinject.com or call 1-855-374-6374. Instructions for use of the Trainer device are provided on the Trainer label. Additional video instructions are available at www.epinephrineautoinject.com.
  • Before injection, make sure you know where to inject (see Figure B) and how to hold the Epinephrine Injection (see Figure C).

 

Make sure Epinephrine Injection has not been used.

Epinephrine Injection has already been used if:

  • the needle is sticking out of the red needle end, and
  • the viewing window is blocked

 

Preparing to Inject a Child

  • If you are administering Epinephrine Injection to a young child, hold their leg firmly in place before and during the 10 second injection to reduce the risk of injury.
  • Ask your healthcare provider to show you how to:
  1. Remove the blue needle shield cap first and then the blue end cap (see Figure D)
  2. Hold the young child firmly in place (restrain movement).
  3. With 1 hand, grip the auto-injector with the RED needle end pointing down.
  4. Inject in the middle of the outer thigh (upper leg) (see Figure B).
d1
d1

d2d2

Figure D. Pull off the blue needle shield cap first and then the blue end cap

  • Keep the Epinephrine Injection away from young children. The Epinephrine Injection is not a toy. Use by young children should be supervised by an adult.
  • After the Epinephrine Injection is used, throw away both the blue needle shield cap and blue end cap immediately. These parts may pose a choking hazard for young children.

Checking the Solution Color

Examine the solution in the viewing window of your Epinephrine Injection regularly. See the information below:

e
e

Figure E. Solution Viewing Window

 

 

How to check the Solution Color:

  • Remove Epinephrine Injection from the carrier tube. See Figure F.
  • The solution can be seen through the viewing window located near the middle of the Epinephrine Injection. See Figure E.
  • To check the solution color, hold the auto-injector in a well-lit area and look into the viewing window.

 

Solution Appearance

✓ Use Epinephrine Injection if the solution is clear and colorless.

X Do not use the Epinephrine Injection if the solution is discolored (pinkish or brown color), cloudy, or contains solid particles. Throw away (dispose of it) and use a new Epinephrine Injection (see “Disposing of an Expired, Unused or Used Epinephrine Injection” on the Patient Information).

 

 

Injecting Epinephrine Injection

Step 1. Remove Epinephrine Injection from the carrier tube. See Figure F.

 

ff

Figure F

Step 2. Pull off the blue needle shield cap first by grasping at the ribbed area and pulling. You will now see a red needle end. Then pull off the blue end cap. See Figure G.

 

Important:

  • The needle comes out of the red needle end.
  • To avoid an accidental injection, never put your thumb, fingers or hand over the red needle end.
  • If an accidental injection occurs, administer a second dose of Epinephrine Injection into the middle of the outer thigh (upper leg) and get emergency medical help right away.
g
g

Figure G

Step 3. Inject the Epinephrine Injection

Self Administration (see Figure H) or Caregiver Administration (see Figure I)

  • Grasp the Epinephrine Injection firmly in your fist with the red needle end pointing downward. See Figure C.
  • Place the red needle end against the middle of the outer thigh (upper leg) at a 90° angle (perpendicular) to the thigh. The injection may be given through clothing if necessary.
  • Press Down Hard and hold Epinephrine Injectionfirmly against the thigh for a full 10 seconds to deliver the medicine. See Figure H and Figure I.

hh

Figure H – Self Administration

II

Figure I – Caregiver Administration

  • Only inject into the middle of the outer thigh (upper leg). Do not inject into any other part of the body.

Step 4. Remove the Auto-Injector

Pull Epinephrine Injection straight out at a 90° angle(perpendicular)from the outer thigh (upper leg).

  • Massage the injection area for 10 seconds.
  • Check the red needle end. The injection is complete and the correct dose has been delivered if you see the needle sticking out of the red needle end.
  • If you do not see the needle, use a new Epinephrine Injection and repeat Step 3.
  • Do not reuse the same Epinephrine Injection.

    Step 5. Get emergency medical help if needed.

    Get emergency medical help for further treatment of the allergic emergency (anaphylaxis), if needed, after using Epinephrine Injection. Before you receive Epinephrine Injection, your healthcare provider should talk to you about when to get emergency medical help.  

    Step 6. After use

    Warning: After Epinephrine Injection is activated, the needle does not retract back into the device.

    After use, carefully place the used Epinephrine Injectionback into the carrier tube to cover the needle.

  • Place the labeled half of the carrier tube on a flat surface, with the opening facing upward.
  • Using 1 hand, carefully slide the red needle end of Epinephrine Injection into the labeled half of the carrier tube until the needle is fully covered. See Figure J.

JJ

Figure J

  • After the needle is inside the labeled half of the carrier tube, firmly push the unlabeled half of the carrier tube over the non-needle end of Epinephrine Injection until it is securely closed. See Figure K.

KK

Figure K

  • Take your used Epinephrine Injection with you when you go to see a healthcare provider.
  • Tell the healthcare provider that you have received an injection of epinephrine. Show the healthcare provider where you received the injection.
  • Give the used Epinephrine Injection to the healthcare provider for inspection and proper disposal.
  • Ask your healthcare provider if you need a new prescription.

StoringEpinephrine Injection

  • Store Epinephrine Injection at room temperature between 68°F to 77°F (20°C to 25°C).
  • Keep Epinephrine Injection in the carrier tube to protect it from light and damage. The carrier tube is not waterproof.
  • Do not expose Epinephrine Injection to extreme heat or cold. For example, do not store in your vehicle’s glove box and do not store it in the refrigerator or freezer.
  • Keep Epinephrine Injection and all medicines out of the reach of children.

Disposing of Epinephrine Injection

Important: The blue needle shield cap and blue end cap are small parts and may pose a choking hazard for children. Throw away the blue needle shield cap and blue end cap immediately after using Epinephrine Injection.

  • Epinephrine Injection has an expiration date. Replace it before the expiration date.
  • For instructions on how to throw away (dispose of) expired, unused, or used Epinephrine Injection, see the section titled “Disposing of an Expired, Unused or Used Epinephrine Injection” on the Patient Information side of this leaflet.

For more information and video instructions on the use of Epinephrine Injection, visit www.epinephrineautoinject.com or call 1-877-835-5472.

© 2025 Amneal Pharmaceuticals LLC. All rights reserved.

Manufactured for and Distributed by:

Amneal Pharmaceuticals LLC

Bridgewater, NJ 08807

1872-06

This Patient Information and Instructions for Use has been approved by the U.S. Food and Drug Administration.

Revised 03/2026

PRINCIPAL DISPLAY PANEL - 0.15 mg CARTON

PACKAGE LABEL.PRINCIPAL DISPLAY PANEL

0-15 carton
0-15 carton

PRINCIPAL DISPLAY PANEL - 0.15 mg WRAP LABEL

PACKAGE LABEL.PRINCIPAL DISPLAY PANEL

0-15 wrap
0-15 wrap

PRINCIPAL DISPLAY PANEL - 0.3 mg CARTON

PACKAGE LABEL.PRINCIPAL DISPLAY PANEL

0-3 carton
0-3 carton

PRINCIPAL DISPLAY PANEL - 0.3 mg WRAP LABEL

PACKAGE LABEL.PRINCIPAL DISPLAY PANEL

0-3 wrap
0-3 wrap

DailyMed RxNorm Mappings#

RxCUI, RxNorm string, TTY table
RxCUIRxNorm stringTTYSPL version
1870225EPINEPHrine (generic for Adrenaclick) 0.15 MG in 0.15 ML Auto-InjectorPSN16
1870230EPINEPHrine (generic for Adrenaclick) 0.3 MG in 0.3 ML Auto-InjectorPSN16
1870225NDA020800 0.15 ML epinephrine 1 MG/ML Auto-InjectorSCD16
1870230NDA020800 0.3 ML epinephrine 1 MG/ML Auto-InjectorSCD16
1870225epinephrine (generic for Adrenaclick) 0.15 MG per 0.15 ML Auto-InjectorSY16
1870230epinephrine (generic for Adrenaclick) 0.3 MG per 0.3 ML Auto-InjectorSY16

DailyMed Pharmacologic Classes#

Class, Version, Type table
ClassVersionTypeEffective
EPINEPHRINE Pharmacologic Class Indexing2Indexing - Pharmacologic Class20180813

Product Linked Resources#

Resource, Code type, Value table
ResourceCode typeValueEquivalent identifiersSource image
BarcodeData Matrix(01)50312345678901(21)123456789012(17)201231(10)123456LGTIN-14: 50312345678901
GTIN storage (14 digits): 50312345678901
epinephrine-injection-14.jpg, epinephrine-injection-16.jpg
BarcodeEAN-130301151694491GTIN-13: 0301151694491
EAN-13: 0301151694491
GTIN-12: 301151694491
UPC-A: 301151694491
GTIN storage (14 digits): 00301151694491
epinephrine-injection-16.jpg
BarcodeEAN-130301151695498GTIN-13: 0301151695498
EAN-13: 0301151695498
GTIN-12: 301151695498
UPC-A: 301151695498
GTIN storage (14 digits): 00301151695498
epinephrine-injection-14.jpg
QR code linkQR Codeepinephrineautoinject.com/epinephrine-injection-14.jpg, epinephrine-injection-16.jpg

DailyMed Product Concepts#

Product concept, Relation, Version table
Product conceptRelationVersionEffective
0b4ec9ca-d305-43fc-88dd-7a510313efe0Product name120260105
bb209f42-a85f-4fee-9d3d-c9dded168625Product name120251208
49628fc7-2031-4c28-bd31-0ef3aa8f44a3Product name320251118
cbf85893-59ef-423f-87d4-a573c000a8b9Product name820250731
b5b1095b-40cd-8a9e-b111-502545045b07Product name420250325
e190029e-423b-473c-8e04-2ada59b5b711Product name120250314
e0031c74-3853-42bc-8e10-86dbbe83992eProduct name220231116
f7046b89-2016-499a-adc6-78479172abc6Product name120230425
2686d634-e712-4007-8dbf-3d37c6c4d71fProduct name120181121
fa8b5901-e681-426f-82fe-54f6d81ec698Product name420180619
bd49bb86-2d32-4a7a-a594-eeda2e29af42Product name120180118
c08ab52f-2fc8-4409-9d9f-ed8edc0bd070Product name120171221
3becbe78-12d9-4ad2-9b4c-1e36f8d1303aProduct name120170815

FDA-Initiated Inactive NDC Indexing#

NDC, Effective, Action table
NDCEffectiveActionDocumentIndexing SPLRelated label
0115-1694-302021-02-05C16284748780-1ba0f9c33-3c09-a910-e053-dadaa90a0b85These highlights do not include all the information needed to use EPINEPHRINE INJECTION safely and effectively. See full prescribing information for EPINEPHRINE INJECTION. EPINEPHRINE injection, for intramuscular or subcutaneous use Initial U.S. Approval: 1939
0115-1694-492021-02-05C16284748780-1ba0f9c33-3c09-a910-e053-dadaa90a0b85These highlights do not include all the information needed to use EPINEPHRINE INJECTION safely and effectively. See full prescribing information for EPINEPHRINE INJECTION. EPINEPHRINE injection, for intramuscular or subcutaneous use Initial U.S. Approval: 1939
0115-1695-302021-02-05C16284748780-1ba0f9c33-3c09-a910-e053-dadaa90a0b85These highlights do not include all the information needed to use EPINEPHRINE INJECTION safely and effectively. See full prescribing information for EPINEPHRINE INJECTION. EPINEPHRINE injection, for intramuscular or subcutaneous use Initial U.S. Approval: 1939
0115-1695-492021-02-05C16284748780-1ba0f9c33-3c09-a910-e053-dadaa90a0b85These highlights do not include all the information needed to use EPINEPHRINE INJECTION safely and effectively. See full prescribing information for EPINEPHRINE INJECTION. EPINEPHRINE injection, for intramuscular or subcutaneous use Initial U.S. Approval: 1939
0115-1694-302021-01-29C16284748780-1ba0f9c33-3c09-a910-e053-dadaa90a0b85These highlights do not include all the information needed to use EPINEPHRINE INJECTION safely and effectively. See full prescribing information for EPINEPHRINE INJECTION. EPINEPHRINE injection, for intramuscular or subcutaneous use Initial U.S. Approval: 1939
0115-1694-492021-01-29C16284748780-1ba0f9c33-3c09-a910-e053-dadaa90a0b85These highlights do not include all the information needed to use EPINEPHRINE INJECTION safely and effectively. See full prescribing information for EPINEPHRINE INJECTION. EPINEPHRINE injection, for intramuscular or subcutaneous use Initial U.S. Approval: 1939
0115-1695-302021-01-29C16284748780-1ba0f9c33-3c09-a910-e053-dadaa90a0b85These highlights do not include all the information needed to use EPINEPHRINE INJECTION safely and effectively. See full prescribing information for EPINEPHRINE INJECTION. EPINEPHRINE injection, for intramuscular or subcutaneous use Initial U.S. Approval: 1939
0115-1695-492021-01-29C16284748780-1ba0f9c33-3c09-a910-e053-dadaa90a0b85These highlights do not include all the information needed to use EPINEPHRINE INJECTION safely and effectively. See full prescribing information for EPINEPHRINE INJECTION. EPINEPHRINE injection, for intramuscular or subcutaneous use Initial U.S. Approval: 1939

DailyMed Package Descriptions#

Package NDC, Product, Description table
Package NDCProductDescriptionFormQuantityStrengthSPL version
0115-1694-30epinephrine1 in 1 CARTONINJECTION116
0115-1694-30epinephrine1 in 1 CASEINJECTION116
0115-1694-49epinephrine2 in 1 CARTONINJECTION216
0115-1694-49epinephrine1 in 1 CASEINJECTION116
0115-1695-30epinephrine1 in 1 CARTONINJECTION116
0115-1695-30epinephrine1 in 1 CASEINJECTION116
0115-1695-49epinephrine1 in 1 CASEINJECTION116
0115-1695-49epinephrine2 in 1 CARTONINJECTION216

DailyMed Billing Units#

Package NDC, Billing unit, Product NDC table
Package NDCBilling unitProduct NDCDailyMed indexing SPLSPL versionEffective
0115-1695-30EA - Each0115-1695e0a9c949-4fcf-498e-9dc2-331621c120e212022-06-06
0115-1695-49EA - Each0115-1695c510929a-2b38-4ef2-bc28-391f0cb6523c12017-03-06
0115-1694-30EA - Each0115-1694d7a54aa3-12ed-470a-9854-11cd9459135712019-06-19
0115-1694-49EA - Each0115-16948f59b63e-d9a0-4426-8607-bce9aae464a212017-03-06

Products#

Every source-derived product name is available through these pages.

DailyMed product names page 1 of 1 · 6 matching rows.

NDC Codes#

Product NDC, Package NDC table
Product NDCPackage NDC
0115-16950115-1695-30, 0115-1695-49
0115-16940115-1694-30, 0115-1694-49

Ingredients#

Every source-derived ingredient row is available through these pages.

DailyMed ingredient rows page 1 of 1 · 12 matching rows.

Source Document#

Source XML · Source PDF

Orange Book application contexts#

All distinct exact application/product contexts derived from this label’s complete NDC list are paginated below.

Orange Book application contexts page 1 of 1 · 1 matching rows.

Source provenance: Browse the complete Orange Book source catalog · source snapshot 43.

Orange Book products#

Current product rows page 1 of 1 · 4 matching rows.

Application-product, Trade name, Ingredient table
Application-productTrade nameIngredientStrengthDosage form / routeTE codesRLD / RSApproval date
N020800-001TWINJECTEPINEPHRINEEQ 0.3MG/DELIVERYINJECTABLE / INTRAMUSCULAR, SUBCUTANEOUS2003-05-30
N020800-002TWINJECTEPINEPHRINEEQ 0.15MG/DELIVERYINJECTABLE / INTRAMUSCULAR, SUBCUTANEOUS2004-05-28
N020800-003ADRENACLICKEPINEPHRINEEQ 0.15MG/DELIVERYINJECTABLE / INTRAMUSCULAR, SUBCUTANEOUSBXRLD, RS2009-11-25
N020800-004ADRENACLICKEPINEPHRINEEQ 0.3MG/DELIVERYINJECTABLE / INTRAMUSCULAR, SUBCUTANEOUSBXRLD, RS2009-11-25

Therapeutic equivalence codes#

Current TE-code rows page 1 of 1 · 2 matching rows.

Application-product, TE code table
Application-productTE code
N020800-003BX
N020800-004BX

Observed Orange Book product history#

Observed FDA ZIP history: Each table is queried independently by exact application/product key from successfully parsed Orange Book snapshots. Capture times identify archived source observations; absence or a change between snapshots is not inferred. FDA publication files that were not recoverable as structured ZIP data are not represented as states.

Product history page 1 of 5 · 172 observed states.

Captured, Edition, Application-product table
CapturedEditionApplication-productTrade nameStrengthDosage form / routeProduct TE source textRLD / RSApproval dateSource SHA-256
2026-09-14 22:38:342026-08N020800-001TWINJECTEQ 0.3MG/DELIVERYINJECTABLE / INTRAMUSCULAR, SUBCUTANEOUS2003-05-3084e616aacf4f…
2026-09-14 22:38:342026-08N020800-002TWINJECTEQ 0.15MG/DELIVERYINJECTABLE / INTRAMUSCULAR, SUBCUTANEOUS2004-05-2884e616aacf4f…
2026-09-14 22:38:342026-08N020800-003ADRENACLICKEQ 0.15MG/DELIVERYINJECTABLE / INTRAMUSCULAR, SUBCUTANEOUSBXRLD, RS2009-11-2584e616aacf4f…
2026-09-14 22:38:342026-08N020800-004ADRENACLICKEQ 0.3MG/DELIVERYINJECTABLE / INTRAMUSCULAR, SUBCUTANEOUSBXRLD, RS2009-11-2584e616aacf4f…
2026-08-18 06:07:402026-07N020800-001TWINJECTEQ 0.3MG/DELIVERYINJECTABLE / INTRAMUSCULAR, SUBCUTANEOUS2003-05-30caaa826d4ba7…
2026-08-18 06:07:402026-07N020800-002TWINJECTEQ 0.15MG/DELIVERYINJECTABLE / INTRAMUSCULAR, SUBCUTANEOUS2004-05-28caaa826d4ba7…
2026-08-18 06:07:402026-07N020800-003ADRENACLICKEQ 0.15MG/DELIVERYINJECTABLE / INTRAMUSCULAR, SUBCUTANEOUSBXRLD, RS2009-11-25caaa826d4ba7…
2026-08-18 06:07:402026-07N020800-004ADRENACLICKEQ 0.3MG/DELIVERYINJECTABLE / INTRAMUSCULAR, SUBCUTANEOUSBXRLD, RS2009-11-25caaa826d4ba7…
2026-02-19 14:30 UTC2026-02N020800-001TWINJECTEQ 0.3MG/DELIVERYINJECTABLE / INTRAMUSCULAR, SUBCUTANEOUS2003-05-30011fe1cb6892…
2026-02-19 14:30 UTC2026-02N020800-002TWINJECTEQ 0.15MG/DELIVERYINJECTABLE / INTRAMUSCULAR, SUBCUTANEOUS2004-05-28011fe1cb6892…
2026-02-19 14:30 UTC2026-02N020800-003ADRENACLICKEQ 0.15MG/DELIVERYINJECTABLE / INTRAMUSCULAR, SUBCUTANEOUSBXRLD, RS2009-11-25011fe1cb6892…
2026-02-19 14:30 UTC2026-02N020800-004ADRENACLICKEQ 0.3MG/DELIVERYINJECTABLE / INTRAMUSCULAR, SUBCUTANEOUSBXRLD, RS2009-11-25011fe1cb6892…
2025-12-14 10:44 UTC · 2 captures of this ZIP2025-12N020800-001TWINJECTEQ 0.3MG/DELIVERYINJECTABLE / INTRAMUSCULAR, SUBCUTANEOUS2003-05-3031067a03dcf5…
2025-12-14 10:44 UTC · 2 captures of this ZIP2025-12N020800-002TWINJECTEQ 0.15MG/DELIVERYINJECTABLE / INTRAMUSCULAR, SUBCUTANEOUS2004-05-2831067a03dcf5…
2025-12-14 10:44 UTC · 2 captures of this ZIP2025-12N020800-003ADRENACLICKEQ 0.15MG/DELIVERYINJECTABLE / INTRAMUSCULAR, SUBCUTANEOUSBXRLD, RS2009-11-2531067a03dcf5…
2025-12-14 10:44 UTC · 2 captures of this ZIP2025-12N020800-004ADRENACLICKEQ 0.3MG/DELIVERYINJECTABLE / INTRAMUSCULAR, SUBCUTANEOUSBXRLD, RS2009-11-2531067a03dcf5…
2025-08-23 18:47 UTC2025-08N020800-001TWINJECTEQ 0.3MG/DELIVERYINJECTABLE / INTRAMUSCULAR, SUBCUTANEOUS2003-05-306a471c1ec25d…
2025-08-23 18:47 UTC2025-08N020800-002TWINJECTEQ 0.15MG/DELIVERYINJECTABLE / INTRAMUSCULAR, SUBCUTANEOUS2004-05-286a471c1ec25d…
2025-08-23 18:47 UTC2025-08N020800-003ADRENACLICKEQ 0.15MG/DELIVERYINJECTABLE / INTRAMUSCULAR, SUBCUTANEOUSBXRLD, RS2009-11-256a471c1ec25d…
2025-08-23 18:47 UTC2025-08N020800-004ADRENACLICKEQ 0.3MG/DELIVERYINJECTABLE / INTRAMUSCULAR, SUBCUTANEOUSBXRLD, RS2009-11-256a471c1ec25d…
2025-03-22 03:13 UTC · 3 captures of this ZIP2025-03N020800-001TWINJECT 0.3EQ 0.3MG/DELIVERYINJECTABLE / INTRAMUSCULAR, SUBCUTANEOUS2003-05-30fd3edfee7708…
2025-03-22 03:13 UTC · 3 captures of this ZIP2025-03N020800-002TWINJECT 0.15EQ 0.15MG/DELIVERYINJECTABLE / INTRAMUSCULAR, SUBCUTANEOUS2004-05-28fd3edfee7708…
2025-03-22 03:13 UTC · 3 captures of this ZIP2025-03N020800-003ADRENACLICKEQ 0.15MG/DELIVERYINJECTABLE / INTRAMUSCULAR, SUBCUTANEOUSBXRLD, RS2009-11-25fd3edfee7708…
2025-03-22 03:13 UTC · 3 captures of this ZIP2025-03N020800-004ADRENACLICKEQ 0.3MG/DELIVERYINJECTABLE / INTRAMUSCULAR, SUBCUTANEOUSBXRLD, RS2009-11-25fd3edfee7708…
2025-02-26 10:13 UTC · 3 captures of this ZIP2025-02N020800-001TWINJECT 0.3EQ 0.3MG/DELIVERYINJECTABLE / INTRAMUSCULAR, SUBCUTANEOUS2003-05-30b8a1b40f171c…
2025-02-26 10:13 UTC · 3 captures of this ZIP2025-02N020800-002TWINJECT 0.15EQ 0.15MG/DELIVERYINJECTABLE / INTRAMUSCULAR, SUBCUTANEOUS2004-05-28b8a1b40f171c…
2025-02-26 10:13 UTC · 3 captures of this ZIP2025-02N020800-003ADRENACLICKEQ 0.15MG/DELIVERYINJECTABLE / INTRAMUSCULAR, SUBCUTANEOUSBXRLD, RS2009-11-25b8a1b40f171c…
2025-02-26 10:13 UTC · 3 captures of this ZIP2025-02N020800-004ADRENACLICKEQ 0.3MG/DELIVERYINJECTABLE / INTRAMUSCULAR, SUBCUTANEOUSBXRLD, RS2009-11-25b8a1b40f171c…
2025-01-19 17:59 UTC · 7 captures of this ZIP2025-01N020800-001TWINJECT 0.3EQ 0.3MG/DELIVERYINJECTABLE / INTRAMUSCULAR, SUBCUTANEOUS2003-05-3003ed91905a0d…
2025-01-19 17:59 UTC · 7 captures of this ZIP2025-01N020800-002TWINJECT 0.15EQ 0.15MG/DELIVERYINJECTABLE / INTRAMUSCULAR, SUBCUTANEOUS2004-05-2803ed91905a0d…
2025-01-19 17:59 UTC · 7 captures of this ZIP2025-01N020800-003ADRENACLICKEQ 0.15MG/DELIVERYINJECTABLE / INTRAMUSCULAR, SUBCUTANEOUSBXRLD, RS2009-11-2503ed91905a0d…
2025-01-19 17:59 UTC · 7 captures of this ZIP2025-01N020800-004ADRENACLICKEQ 0.3MG/DELIVERYINJECTABLE / INTRAMUSCULAR, SUBCUTANEOUSBXRLD, RS2009-11-2503ed91905a0d…
2024-12-13 21:23 UTC · 2 captures of this ZIP2024-12N020800-001TWINJECT 0.3EQ 0.3MG/DELIVERYINJECTABLE / INTRAMUSCULAR, SUBCUTANEOUS2003-05-302680178bc6a6…
2024-12-13 21:23 UTC · 2 captures of this ZIP2024-12N020800-002TWINJECT 0.15EQ 0.15MG/DELIVERYINJECTABLE / INTRAMUSCULAR, SUBCUTANEOUS2004-05-282680178bc6a6…
2024-12-13 21:23 UTC · 2 captures of this ZIP2024-12N020800-003ADRENACLICKEQ 0.15MG/DELIVERYINJECTABLE / INTRAMUSCULAR, SUBCUTANEOUSBXRLD, RS2009-11-252680178bc6a6…
2024-12-13 21:23 UTC · 2 captures of this ZIP2024-12N020800-004ADRENACLICKEQ 0.3MG/DELIVERYINJECTABLE / INTRAMUSCULAR, SUBCUTANEOUSBXRLD, RS2009-11-252680178bc6a6…
2024-09-14 05:58 UTC · 2 captures of this ZIP2024-09N020800-001TWINJECT 0.3EQ 0.3MG/DELIVERYINJECTABLE / INTRAMUSCULAR, SUBCUTANEOUS2003-05-305bbf6a4d5a75…
2024-09-14 05:58 UTC · 2 captures of this ZIP2024-09N020800-002TWINJECT 0.15EQ 0.15MG/DELIVERYINJECTABLE / INTRAMUSCULAR, SUBCUTANEOUS2004-05-285bbf6a4d5a75…
2024-09-14 05:58 UTC · 2 captures of this ZIP2024-09N020800-003ADRENACLICKEQ 0.15MG/DELIVERYINJECTABLE / INTRAMUSCULAR, SUBCUTANEOUSBXRLD, RS2009-11-255bbf6a4d5a75…
2024-09-14 05:58 UTC · 2 captures of this ZIP2024-09N020800-004ADRENACLICKEQ 0.3MG/DELIVERYINJECTABLE / INTRAMUSCULAR, SUBCUTANEOUSBXRLD, RS2009-11-255bbf6a4d5a75…

Observed Orange Book normalized TE history#

Normalized TE history page 1 of 3 · 86 observed states.

Captured, Edition, Application-product table
CapturedEditionApplication-productTE codeOrderSource SHA-256
2026-09-14 22:38:342026-08N020800-003BX184e616aacf4f…
2026-09-14 22:38:342026-08N020800-004BX184e616aacf4f…
2026-08-18 06:07:402026-07N020800-003BX1caaa826d4ba7…
2026-08-18 06:07:402026-07N020800-004BX1caaa826d4ba7…
2026-02-19 14:30 UTC2026-02N020800-003BX1011fe1cb6892…
2026-02-19 14:30 UTC2026-02N020800-004BX1011fe1cb6892…
2025-12-14 10:44 UTC · 2 captures of this ZIP2025-12N020800-003BX131067a03dcf5…
2025-12-14 10:44 UTC · 2 captures of this ZIP2025-12N020800-004BX131067a03dcf5…
2025-08-23 18:47 UTC2025-08N020800-003BX16a471c1ec25d…
2025-08-23 18:47 UTC2025-08N020800-004BX16a471c1ec25d…
2025-03-22 03:13 UTC · 3 captures of this ZIP2025-03N020800-003BX1fd3edfee7708…
2025-03-22 03:13 UTC · 3 captures of this ZIP2025-03N020800-004BX1fd3edfee7708…
2025-02-26 10:13 UTC · 3 captures of this ZIP2025-02N020800-003BX1b8a1b40f171c…
2025-02-26 10:13 UTC · 3 captures of this ZIP2025-02N020800-004BX1b8a1b40f171c…
2025-01-19 17:59 UTC · 7 captures of this ZIP2025-01N020800-003BX103ed91905a0d…
2025-01-19 17:59 UTC · 7 captures of this ZIP2025-01N020800-004BX103ed91905a0d…
2024-12-13 21:23 UTC · 2 captures of this ZIP2024-12N020800-003BX12680178bc6a6…
2024-12-13 21:23 UTC · 2 captures of this ZIP2024-12N020800-004BX12680178bc6a6…
2024-09-14 05:58 UTC · 2 captures of this ZIP2024-09N020800-003BX15bbf6a4d5a75…
2024-09-14 05:58 UTC · 2 captures of this ZIP2024-09N020800-004BX15bbf6a4d5a75…
2024-11-08 22:44 UTC · 3 captures of this ZIP2024-11N020800-003BX1d8e5a09893c0…
2024-11-08 22:44 UTC · 3 captures of this ZIP2024-11N020800-004BX1d8e5a09893c0…
2024-10-29 15:01 UTC2024-10N020800-003BX1d06236e962d9…
2024-10-29 15:01 UTC2024-10N020800-004BX1d06236e962d9…
2024-08-13 05:28 UTC · 3 captures of this ZIP2024-08N020800-003BX179d66fd596c7…
2024-08-13 05:28 UTC · 3 captures of this ZIP2024-08N020800-004BX179d66fd596c7…
2024-07-13 05:37 UTC · 2 captures of this ZIP2024-07N020800-003BX1301d65b070ca…
2024-07-13 05:37 UTC · 2 captures of this ZIP2024-07N020800-004BX1301d65b070ca…
2024-06-18 03:08 UTC · 5 captures of this ZIP2024-06N020800-003BX11e350fbaab3a…
2024-06-18 03:08 UTC · 5 captures of this ZIP2024-06N020800-004BX11e350fbaab3a…
2024-05-31 18:47 UTC2024-05N020800-003BX18072bd15b7f6…
2024-05-31 18:47 UTC2024-05N020800-004BX18072bd15b7f6…
2022-06-29 02:47 UTC · 2 captures of this ZIP2022-06N020800-003BX15c6f7cd8ea54…
2022-06-29 02:47 UTC · 2 captures of this ZIP2022-06N020800-004BX15c6f7cd8ea54…
2022-04-08 23:34 UTC2022-04N020800-003BX15d02ea3f76ae…
2022-04-08 23:34 UTC2022-04N020800-004BX15d02ea3f76ae…
2022-04-04 05:41 UTC2022-04N020800-003BX14b0b4de00fa7…
2022-04-04 05:41 UTC2022-04N020800-004BX14b0b4de00fa7…
2019-12-13 00:20 UTC2019-12N020800-003BX174a2ff9319b5…
2019-12-13 00:20 UTC2019-12N020800-004BX174a2ff9319b5…

Observed Orange Book patent history#

Patent history page 1 of 5 · 182 observed states.

Captured, Edition, Application-product table
CapturedEditionApplication-productPatentExpirationUse codeCoverage / statusSubmission dateSource SHA-256
2022-06-29 02:47 UTC · 2 captures of this ZIP2022-06N020800-00172971362025-01-18Drug product5c6f7cd8ea54…
2022-06-29 02:47 UTC · 2 captures of this ZIP2022-06N020800-00176218912025-02-04Drug product5c6f7cd8ea54…
2022-06-29 02:47 UTC · 2 captures of this ZIP2022-06N020800-00272971362025-01-18Drug product5c6f7cd8ea54…
2022-06-29 02:47 UTC · 2 captures of this ZIP2022-06N020800-00276218912025-02-04Drug product5c6f7cd8ea54…
2022-06-29 02:47 UTC · 2 captures of this ZIP2022-06N020800-003101663342025-01-21Drug product2020-02-115c6f7cd8ea54…
2022-06-29 02:47 UTC · 2 captures of this ZIP2022-06N020800-00379053522027-04-12Drug product2017-06-025c6f7cd8ea54…
2022-06-29 02:47 UTC · 2 captures of this ZIP2022-06N020800-004101663342025-01-21Drug product2020-02-115c6f7cd8ea54…
2022-06-29 02:47 UTC · 2 captures of this ZIP2022-06N020800-00479053522027-04-12Drug product2017-06-025c6f7cd8ea54…
2022-04-08 23:34 UTC2022-04N020800-00172971362025-01-18Drug product5d02ea3f76ae…
2022-04-08 23:34 UTC2022-04N020800-00176218912025-02-04Drug product5d02ea3f76ae…
2022-04-08 23:34 UTC2022-04N020800-00272971362025-01-18Drug product5d02ea3f76ae…
2022-04-08 23:34 UTC2022-04N020800-00276218912025-02-04Drug product5d02ea3f76ae…
2022-04-08 23:34 UTC2022-04N020800-003101663342025-01-21Drug product2020-02-115d02ea3f76ae…
2022-04-08 23:34 UTC2022-04N020800-00379053522027-04-12Drug product2017-06-025d02ea3f76ae…
2022-04-08 23:34 UTC2022-04N020800-004101663342025-01-21Drug product2020-02-115d02ea3f76ae…
2022-04-08 23:34 UTC2022-04N020800-00479053522027-04-12Drug product2017-06-025d02ea3f76ae…
2022-04-04 05:41 UTC2022-04N020800-00172971362025-01-18Drug product4b0b4de00fa7…
2022-04-04 05:41 UTC2022-04N020800-00176218912025-02-04Drug product4b0b4de00fa7…
2022-04-04 05:41 UTC2022-04N020800-00272971362025-01-18Drug product4b0b4de00fa7…
2022-04-04 05:41 UTC2022-04N020800-00276218912025-02-04Drug product4b0b4de00fa7…
2022-04-04 05:41 UTC2022-04N020800-003101663342025-01-21Drug product2020-02-114b0b4de00fa7…
2022-04-04 05:41 UTC2022-04N020800-00379053522027-04-12Drug product2017-06-024b0b4de00fa7…
2022-04-04 05:41 UTC2022-04N020800-004101663342025-01-21Drug product2020-02-114b0b4de00fa7…
2022-04-04 05:41 UTC2022-04N020800-00479053522027-04-12Drug product2017-06-024b0b4de00fa7…
2019-12-13 00:20 UTC2019-12N020800-00172971362025-01-18Drug product74a2ff9319b5…
2019-12-13 00:20 UTC2019-12N020800-00176218912025-02-04Drug product74a2ff9319b5…
2019-12-13 00:20 UTC2019-12N020800-00272971362025-01-18Drug product74a2ff9319b5…
2019-12-13 00:20 UTC2019-12N020800-00276218912025-02-04Drug product74a2ff9319b5…
2019-12-13 00:20 UTC2019-12N020800-00379053522027-04-12Drug product2017-06-0274a2ff9319b5…
2019-12-13 00:20 UTC2019-12N020800-00479053522027-04-12Drug product2017-06-0274a2ff9319b5…
2022-03-09 01:35 UTC2022-03N020800-00172971362025-01-18Drug productbb7c543d1eb4…
2022-03-09 01:35 UTC2022-03N020800-00176218912025-02-04Drug productbb7c543d1eb4…
2022-03-09 01:35 UTC2022-03N020800-00272971362025-01-18Drug productbb7c543d1eb4…
2022-03-09 01:35 UTC2022-03N020800-00276218912025-02-04Drug productbb7c543d1eb4…
2022-03-09 01:35 UTC2022-03N020800-003101663342025-01-21Drug product2020-02-11bb7c543d1eb4…
2022-03-09 01:35 UTC2022-03N020800-00379053522027-04-12Drug product2017-06-02bb7c543d1eb4…
2022-03-09 01:35 UTC2022-03N020800-004101663342025-01-21Drug product2020-02-11bb7c543d1eb4…
2022-03-09 01:35 UTC2022-03N020800-00479053522027-04-12Drug product2017-06-02bb7c543d1eb4…
2021-12-28 21:50 UTC2021-12N020800-00172971362025-01-18Drug product782e0a99824c…
2021-12-28 21:50 UTC2021-12N020800-00176218912025-02-04Drug product782e0a99824c…

openFDA label cross-check#

OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.

Matched openFDA labels page 1 of 1 · 1 matching rows.

Brand, Generic, Manufacturer table
BrandGenericManufacturerSPL set IDEffective dateAvailable safety fieldsJoin
epinephrineEPINEPHRINEAmneal Pharmaceuticals of New York LLCe13f05f1-7d21-49bb-b8d5-24bf9301c3d72026-03-20Warnings, Adverse reactionsExact identifier
ndc (package): 0115-1694-49
ndc (package): 0115-1695-30
ndc (package): 0115-1695-49
ndc (package): 0115-1694-30
ndc (product): 0115-1695
ndc (product): 0115-1694
ndc11 (package): 00115169530
ndc11 (package): 00115169449
ndc11 (package): 00115169549
ndc11 (package): 00115169430
spl id: fdafd090-bed3-4f16-8ab1-fd1573aa633e
spl set id: e13f05f1-7d21-49bb-b8d5-24bf9301c3d7

Reported adverse events (FAERS/openFDA)#

Adverse event summaries are temporarily unavailable. Other product information remains available.